ALX-0651 is a dual-complementarity-determining region humanized monoclonal antibody inhibitor targeting CXCR4. It can inhibit the transport of hematopoietic stem cells as well as the progression and metastasis of tumors. ALX-0651 is applicable for research in treating non-Hodgkins lymphoma and multiple myeloma.
Target:
CXCR
* VAT and and shipping costs not included. Errors and price changes excepted